Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial

• DOI: 10.1111/dom.15464
• Publication Date: 2024-01-19T09:08:58Z
• Authors: Liv Vernstrøm; Søren Gullaksen; Steffen S. Sørensen; Kristian L. Funck; Esben Laugesen; Per L. Poulsen
• Keywords: Empagliflozin; Semaglutide; Dapagliflozin; Microalbuminuria; Albuminuria

Abstract Aim Despite the increasing use of combination treatment with sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide‐1 receptor agonists, data are limited on effects markers cardiovascular disease. This study aimed to investigate effect empagliflozin, semaglutide, their vascular function. Materials Methods In total, 120 patients type diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, combination. The had two co‐primary outcomes: change arterial stiffness kidney oxygenation. paper reports assessed as carotid‐femoral pulse wave velocity. Secondary outcomes included 24‐h blood pressure (BP), central BP, urinary albumin creatinine ratio glycaemic control by both continuous glucose monitoring glycated haemoglobin. Results velocity did not significantly any compared placebo. Twenty‐four‐hour systolic BP was reduced 10 mmHg (95% CI 6–14), p < .001 group, superior placebo monotherapy ( .05). Combination increased time range from 72% at baseline 91% week 32, .001, without below range. decreased 36% 4–57), .03 group Conclusions Empagliflozin, or reduce stiffness. showed a substantial clinically important reduction either alone. risk hypoglycaemia.